股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

Financial Performance - For the fiscal year ending December 31, 2025, the company reported total revenue of HKD 677,121,000, representing a 30.2% increase from HKD 519,699,000 in the previous year[2] - The gross profit for the same period was HKD 23,598,000, down 20.5% from HKD 29,670,000 in the prior year[2] - The net profit attributable to the owners of the company was HKD 5,941,000, a significant increase from HKD 1,311,000, marking a 353.5% growth year-over-year[2] - The basic and diluted earnings per share rose to HKD 3.51 from HKD 0.77, reflecting a 354.5% increase[2] - The adjusted operating profit for the year was HKD 5,943,000, a significant increase from HKD 1,311,000 in the previous year[29] - Net profit for the year ended December 31, 2025, was HKD 9,000,000, compared to HKD 6,000,000 for 2024, reflecting a significant increase[31] - The group recorded a profit attributable to owners of approximately HKD 5.9 million, a significant improvement from HKD 1.3 million in the previous year[50] Assets and Liabilities - Total assets as of December 31, 2025, were HKD 408,386,000, slightly up from HKD 407,309,000 in the previous year[4] - The company reported total liabilities of HKD 17,186,000, a decrease of 21.5% from HKD 21,739,000 in the prior year[5] - Cash and cash equivalents increased to HKD 61,385,000 from HKD 23,258,000, indicating a growth of 163.5%[4] - Trade and other receivables rose to HKD 272,497,000 from HKD 174,146,000, representing a 56.5% increase[4] - Total trade receivables increased to HKD 225,478,000 in 2025 from HKD 99,004,000 in 2024, marking a growth of approximately 128%[33] - The net trade receivables after expected credit loss provisions were HKD 222,670,000 in 2025, up from HKD 98,746,000 in 2024[33] - Expected credit loss provisions for trade receivables increased to approximately HKD 2.6 million from HKD 0.3 million in 2024, reflecting a more cautious approach to credit risk management[49] Revenue Breakdown - Revenue from health products and food amounted to HKD 66,516,000, while electronic components generated HKD 610,605,000 in revenue[20] - Revenue from the Hong Kong market was HKD 675,978,000 in 2025, up from HKD 519,699,000 in 2024, showing a growth of approximately 30%[25] - The group's revenue increased by approximately 30.3% to about HKD 677.1 million for the year ended December 31, 2025, compared to HKD 519.7 million in 2024[47] Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to drive future growth[7] - The company is diversifying its product portfolio by entering the health products market, launching ginseng wine aimed at health-conscious consumers[45] - The company is actively establishing a supplier network and customer relationships for its new health products[46] - The group plans to invest in new production facilities in China and other locations to enhance production capacity and service offerings[51] - The group is actively expanding its health segment by exploring partnerships with skincare and health supplement companies[52] Corporate Governance and Compliance - The board is committed to high standards of corporate governance and has complied with the applicable corporate governance code[68] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's audited financial statements for the year[70] - The annual results announcement will be published on the stock exchange and the company's website, with the annual report to be sent to shareholders as required[74] Legal and Regulatory Matters - The company is facing a legal lawsuit from a supplier claiming unpaid amounts totaling CAD 2.8 million (approximately HKD 14.8 million), but management believes the claims lack merit and will not significantly impact the group's financial position[61] - The company did not recommend any dividends for the years ended December 31, 2025, and 2024[32] - The board of directors has not recommended a final dividend for the fiscal year 2024[62] Operational Changes - The group’s cash flow statement will now start from the operating profit subtotal due to the new accounting standard[16] - The company is implementing strategic bulk procurement to manage inventory levels effectively in a constrained supply environment[44] - Trade payables increased to HKD 15,570,000 in 2025 from zero in 2024, indicating a shift in the company's payment obligations[36] - As of December 31, 2025, the current ratio was approximately 22.6 times, up from 18.1 times in 2024[53] - As of December 31, 2025, the group has a total of 19 employees, with salary adjustments based on performance reviews and individual contributions[63] - The company adopted a stock option plan on June 27, 2024, but no stock options have been granted under this plan during the year[64] - As of December 31, 2025, the group has no significant contingent liabilities[65] - There have been no significant events affecting the group's operations and financial performance since the end of the fiscal year until the date of this announcement[66] - The company and its subsidiaries did not purchase, sell, or redeem any of its listed securities during the year[67]

董事會會議日期 前海健康控股有限公司（「本公司」）董事（「董事」）組成之董事會（「董事會」） 謹此宣佈，本公司董事會會議將於二零二六年三月十八日（星期三）舉行，以（其 中包括）批准本公司及其附屬公司截至二零二五年十二月三十一日止之經審核財 政年度業績及其刊發，並及考慮派發末期股息之建議（如有）。 承董事會命 前海健康控股有限公司 主席 黃志群先生 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Qianhai Health Holdings Limited 前海健康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：911） 香港，二零二六年三月四日 於本公告日期，非執行董事為黃志群先生、陳凱犇先生及陳琦先生；執行董事為 湯裕源及源自立先生; 及獨立非執行董事為李煒先生、梁振東先生及吳鴻茹女 士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

Group 1 - The company expects to achieve a shareholder profit ranging from HKD 5 million to HKD 6 million for the year ending December 31, 2025, compared to approximately HKD 1.3 million for the year ending December 31, 2024 [1] - The improvement in the company's consolidated net profit is primarily attributed to the absence of provisions for loss contracts in the fiscal year [1]

Core Viewpoint - Qianhai Health (00911) expects to achieve a shareholder profit ranging from HKD 5 million to HKD 6 million for the fiscal year ending December 31, 2025, compared to approximately HKD 1.3 million for the fiscal year ending December 31, 2024. The improvement in consolidated net profit is primarily attributed to the absence of provisions for loss contracts in the fiscal year [1]. Financial Performance - The projected shareholder profit for the fiscal year ending December 31, 2025, is between HKD 5 million and HKD 6 million [1]. - The estimated shareholder profit for the fiscal year ending December 31, 2024, is approximately HKD 1.3 million [1]. - The improvement in net profit is mainly due to not recognizing loss contract provisions during the fiscal year [1].

Core Viewpoint - Qianhai Health (00911.HK) expects to record a profit attributable to shareholders ranging from HKD 5 million to HKD 6 million for the year ending December 31, 2025, compared to approximately HKD 1.3 million for the year ending December 31, 2024, indicating a significant improvement in net profit due to the absence of loss contract provisions in the fiscal year [1] Financial Performance - The expected profit for the year ending December 31, 2025, is projected to be between HKD 5 million and HKD 6 million [1] - The profit attributable to shareholders for the year ending December 31, 2024, is approximately HKD 1.3 million [1] - The improvement in consolidated net profit is primarily attributed to the lack of loss contract provisions in the fiscal year [1]

本公司仍在落實財政年度之未經審核年度業績。本公告所載資料僅為董事會根據財政年度之管 理賬目及目前可獲得之最新資料作出的初步評估，該等資料並未經本公司審計師或審核委員會 審閱，並可能須予調整。集團財政年度之實際財務業績可能與本公告所披露者有所差異。有關 本集團財務業績及表現之進一步詳情將於本公司之財政年度業績公告中披露，預計該公告將根 據上市規則的規定於二零二六年三月刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前海健康控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號：911) 正面盈利預告 本公告由前海健康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「 董 事」）會（「 董事會」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09 條及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）作出。 董事會謹 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年12月31日 狀態 ...